Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of TP-04 in Participants With Papulopustular Rosacea

NCT05838170 is registered in ClinicalTrials.gov with Tarsus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05838170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05838170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of TP-04 in Participants With Papulopustular Rosacea
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2023
Completion date
November 13, 2023
Enrollment
37 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

papulopustular rosacea